文献速递腹部技术与安全CT

治疗前增强CT结直肠癌肝转移灶纹理特征可预测含贝伐珠单抗化疗的疗效与预后:一项与标准化疗比较的初步研究

Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
PubMed 文献 · Radiol Med · 2019-06-06

回顾性纳入43例结直肠癌肝转移患者,A组23例接受含贝伐珠单抗化疗,B组20例接受标准化疗。治疗前增强CT纹理分析参数均匀性在A组应答者中较低,且均匀性与影像学应答、总生存和无进展生存独立相关,B组无变量相关。

要点

  • 治疗前增强CT纹理参数均匀性较低可能提示含贝伐珠单抗化疗应答更好。
  • 均匀性仅在贝伐珠单抗组与影像学应答、总生存及无进展生存独立相关。
  • 标准化疗组中无纹理或密度变量与应答及预后相关。

核心结论

  • 治疗前增强CT纹理分析可对含贝伐珠单抗治疗的结直肠癌肝转移患者的应答概率和预后进行分层。
  • 该结果仅见于贝伐珠单抗组,标准化疗组无变量与影像学应答、总生存或无进展生存相关。

研究设计与样本

  • 回顾性研究,共纳入43例结直肠癌肝转移患者。
  • A组23例接受含贝伐珠单抗化疗,B组20例接受标准化疗。
  • 对治疗前增强CT的目标肝病灶进行纹理分析,获得描述病灶异质性的参数均匀性。
  • 治疗后3个月按RECIST-1.1标准评估影像学应答。
  • 结局指标为总生存和无进展生存,采用多因素logistic回归和生存分析。

关键影像表现/征象

  • A组应答者的均匀性低于非应答者(p < 0.001),B组无此差异。
  • 两组中非应答者的病灶CT密度均较低(分别为p = 0.03和p = 0.02)。

诊断标准与关键数值

  • 纹理分析参数为均匀性,用于描述病灶异质性。
  • 影像学应答按RECIST-1.1标准于治疗后3个月分类。
  • A组中均匀性与影像学应答独立相关(比值比 = 20,p = 0.01)。
  • A组中均匀性与总生存和无进展生存相关(相对风险分别为6.94和5.05;p = 0.005和p = 0.004)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Bevacizumab added to chemotherapy can improve survival in patients with metastatic colorectal cancer, but no predictive factors of efficacy are available in clinical practice. The aim of this study is to assess the predictive and prognostic value of texture analysis on pretreatment contrast-enhanced CT in patients affected by colorectal liver metastases.

MATERIALS AND METHODS: Forty-three patients with colorectal liver metastases were retrospectively included in the study: 23 treated with bevacizumab-containing chemotherapy (group A), and 20 with standard chemotherapy (group B). Target liver lesions were analyzed by texture analysis of pretreatment contrast-enhanced CT. Texture analysis produced the parameter uniformity, describing lesion heterogeneity. Radiological response was classified after 3 months according to RECIST-1.1. Overall survival (OS) and progression-free survival (PFS) were considered to be outcome indicators. Multivariable logistic regression and survival analysis were performed.

RESULTS: Uniformity was lower in responders than in nonresponders (p < 0.001) in group A but not in group B. Lesion CT density was lower in nonresponders in both groups (p = 0.03 and 0.02, respectively). In group A, uniformity was independently correlated with radiological response (odds ratio = 20, p = 0.01), OS and PFS (relative risks 6.94 and 5.05, respectively; p = 0.005 and p = 0.004, respectively). In group B, no variables were correlated with radiological response, OS or PFS.

CONCLUSION: Texture analysis on contrast-enhanced CT stratified response probability and prognosis in patients with colorectal liver metastases treated with bevacizumab-containing therapy. This result was specific for the bevacizumab group.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Ravanelli M, Agazzi GM, Tononcelli E, et al. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. Radiol Med. 2019. PMID: 31172448. doi:10.1007/s11547-019-01046-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。